ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 517

A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs

Mark Genovese1, Kurt de Vlam 2, Jacques-Eric Gottenberg 3, Beatrix Bartok 4, Iyabode Tiamiyu 4, Ying Guo 4, Chantal Tasset 5, John Sundy 4, David Walker 6, Tsutomu Takeuchi 7 and Kenneth Kalunian 8, 1Stanford University, Stanford, CA, 2Department of Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium, 3Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, 4Gilead Sciences, Inc., Foster City, CA, 5Galapagos NV, Mechelen, Belgium, 6Northumbria Healthcare, Northumbria, United Kingdom, 7Division of Rheumatology, Keio University School of Medicine, Tokyo, Japan, 8Division of Rheumatology, Allergy, and Immunology, University of California San Diego, La Jolla, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Treatments Poster I: Novel Treatments

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: There is an unmet medical need to treat RA in patients who have failed prior biologic DMARD treatments (biologic DMARD inadequate response; bDMARD-IR), some of which target the IL-6 pathway. Patients who are bDMARD-IR are considered more treatment resistant and have more variable responses to treatment than treatment- or bDMARD-naïve patients. Questions remain as to whether the clinical efficacy of the oral, selective Janus kinase (JAK)-1 inhibitor filgotinib differs among patients with prior exposure to IL-6 inhibitors. We explored the efficacy of filgotinib in bDMARD-IR patients with active RA based on number and mechanism of action (MOA) of prior biologics.

Methods: The global, phase 3 FINCH-2 (NCT02873936) study enrolled 449 bDMARD-IR patients with active RA, who were randomized in a 1:1:1 manner to receive once-daily filgotinib 200 mg, filgotinib 100 mg, or placebo for 24 weeks.1 This subgroup analysis evaluated filgotinib efficacy respective to the number and MOA of prior bDMARD use. Clinical efficacy was assessed using ACR20, DAS28(CRP) for low disease activity and remission, and patient-reported outcomes at weeks 12 and 24. Quality-of-life outcomes were assessed by change in HAQ disability index (HAQ-DI), change in SF-36-Physical Component score, and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) at weeks 12 and 24.

Results: Of the 448 patients randomized and treated at baseline, 80.4% were female with a mean age of 56 years and a mean RA duration of 12.4 years. Prior bDMARD exposure, including the total number and MOA, was well balanced amongst the 3 treatment arms. Clinical efficacy outcomes—as measured by ACR20, DAS28(CRP) ≤3.2, and DAS28(CRP) < 2.6—are provided in Table 1. Quality-of-life outcomes—as measured by change in HAQ-DI, change in SF-36-Physical Component score, and FACIT-F at week 12—are provided in Table 2.

Conclusion: Compared with placebo, filgotinib demonstrated improved clinical outcomes in bDMARD refractory patients. The efficacy observed with filgotinib was maintained with no significant effects based on the number and MOA of prior bDMARD use, including in patients with prior exposure to IL-6 inhibitors.  

References:

1. Genovese MC, et al. Safety and Efficacy of Filgotinib in a Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic Dmards [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10).


Table 1_DMARDs

Table 1. Efficacy outcomes ACR20, DAS28-CRP- for low disease activity and remission at week 12 relative to prior bDMARD use
Data presented as n -%- unless otherwise specified.
bDMARD, biologic DMARD; CI, confidence interval; FIL, filgotinib; MOA, mechanism of action; PBO, placebo; QD, once daily.


Table 2_DMARDs

Table 2. Quality of life outcomes HAQ-DI, SF-36 physical component, and FACIT-F change from baseline at week 12 with respect to prior bDMARD use
Data presented as mean -SD- unless otherwise specified.
bDMARD, biologic DMARD; CI, confidence interval; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FIL, filgotinib; LSM, least squares mean; MOA, mechanism of action; PBO, placebo; PCS, physical component summary; QD, once daily; SD, standard deviation.


Disclosure: M. Genovese, AbbVie, 2, 5, Abbvie, 2, 5, AbbVie, Inc., 9, Astellas, 2, 5, Eli Lilly, 2, 5, Eli Lilly and Company, 2, 5, EMD Merck Serono, 2, 5, Galapagos, 2, 5, Galapagos NV, 2, 5, 9, Genentech/Roche, 2, 5, Gilead, 2, 5, Gilead Science, 9, Gilead Sciences, Inc., 2, 5, 9, GSK, 5, Lilly, 2, 5, 9, Novartis, 2, 5, Pfizer, 2, 5, 9, Pfizer Inc, 2, 5, Pfizer, Inc., 9, Pzier, 9, RPharm, 5, Sanofi Genzyme, 2, 5, Vertex, 2, 5; K. de Vlam, Celgene, 5, 8, Eli Lilly, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, UCB, 5, 8; J. Gottenberg, Abbvie, 8, BMS, 2, 5, Lilly, 5, 8, Pfizer, 2, 5, Roche, 8, Sanofi-Genzyme, 5, 8, UCB, 5, 8; B. Bartok, Gilead Sciences, Inc., 3, 4; I. Tiamiyu, Gilead Sciences, Inc., 3, 4; Y. Guo, Gilead Sciences, Inc., 3, 4; C. Tasset, Galapagos, 1, 3, Galapagos NV, 3, 4; J. Sundy, Gilead Sciences, Inc., 3, 4; D. Walker, BMS, 8, Gilead Sciences, Inc., 8, Lilly, 8, Novartis, 8, Pfizer, 8; T. Takeuchi, None; K. Kalunian, AbbVie, 9, Abbvie, 5, Amgen, 5, AstraZeneca, 5, Biogen, 5, 9, BMS, 2, 9, Chemocentryx, 5, Eli Lilly, 5, 9, Equillium, 5, Exagen, 2, Genentech/Roche, 5, Gilead, 9, Gilead Sciences, Inc., 9, GSK, 5, Idosia, 2, Janssen, 5, Kirin, 2, MedImmune, 5, Nektar, 5, Pfizer, 2, Resolve, 2, Roche, 9, Takeda, 2, UCB, 2.

To cite this abstract in AMA style:

Genovese M, de Vlam K, Gottenberg J, Bartok B, Tiamiyu I, Guo Y, Tasset C, Sundy J, Walker D, Takeuchi T, Kalunian K. A Subgroup Analysis of Clinical Efficacy Response and Quality of Life Outcomes from Phase 3 Study of Filgotinib in Patients with Inadequate Response to Biologic DMARDs [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-subgroup-analysis-of-clinical-efficacy-response-and-quality-of-life-outcomes-from-phase-3-study-of-filgotinib-in-patients-with-inadequate-response-to-biologic-dmards/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-subgroup-analysis-of-clinical-efficacy-response-and-quality-of-life-outcomes-from-phase-3-study-of-filgotinib-in-patients-with-inadequate-response-to-biologic-dmards/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology